Abstract: Provided is a method for preparing a peptide emulsion formulation capable of preparing a desired peptide emulsion formulation. A method for preparing a peptide emulsion formulation includes a step of mixing an aqueous solution containing a compound consisting of an amino acid sequence represented by Formula (1), a pharmaceutically acceptable salt thereof, and a peptide consisting of an amino acid sequence represented by WAPVLDFAPPGASAYGSL (SEQ ID NO: 1) or a pharmaceutically acceptable salt thereof with an oily formulation and applying vibration mixing; and a membrane emulsification step of passing a premixed solution after the vibration mixing through a membrane filter to emulsify the premixed solution.

Abstract: The present invention provides an injectable pharmaceutical composition containing the following components: (a) one or more kinds of peptides selected from a peptide represented by the formula (1): wherein the bond between Cys and Cys is a disulfide bond, Leu-OH shows that the C-terminal of Leu is a free carboxyl group, and other bond is a peptide bond, a peptide consisting of the amino acid sequence shown by Trp-Ala-Pro-Val-Leu-Asp-Phe-Ala-Pro-Pro-Gly-Ala-Ser-Ala-Tyr-Gly-Ser-Leu (SEQ ID NO: 1) and salts thereof, (b) trehalose or trehalose hydrate, and (c) a pH adjuster.

Abstract: The present invention provides an injectable pharmaceutical composition containing the following components: (a) one or more kinds of peptides selected from a peptide represented by the formula (1): wherein the bond between Cys and Cys is a disulfide bond, Leu-OH shows that the C-terminal of Leu is a free carboxyl group, and other bond is a peptide bond, a peptide consisting of the amino acid sequence shown by Trp-Ala-Pro-Val-Leu-Asp-Phe-Ala-Pro-Pro-Gly-Ala-Ser-Ala-Tyr-Gly-Ser-Leu (SEQ ID NO: 1) and salts thereof, (b) trehalose or trehalose hydrate, and (c) a pH adjuster.

Abstract: The invention provides an aqueous liquid composition comprising a WT1 protein-derived cancer antigen peptide, wherein the peptide is stabilized. The aqueous liquid composition contains a peptide and an excipient, and has a pH of 3-6. The peptide has the amino acid sequence Arg-Met-Phe-Pro-Asn-Ala-Pro-Tyr-Leu (SEQ ID NO: 1), wherein optionally 1 to 3 amino acids are deleted, substituted and/or added, such that the peptide has a cytotoxic T cell-inducing ability. The excipient is (a) an alpha hydroxyl acid selected from glycolic acid, lactic acid, malic acid, tartaric acid, citric acid and pharmacologically acceptable salts thereof, (b) a dicarboxylic acid selected from malonic acid, succinic acid, glutaric acid, maleic acid and pharmacologically acceptable salts thereof, and/or (c) methionine.

Abstract: The invention provides an aqueous liquid composition comprising a WT1 protein-derived cancer antigen peptide, wherein the peptide is stabilized. The aqueous liquid composition contains a peptide and an excipient, and has a pH of 3-6. The peptide has the amino acid sequence Arg-Met-Phe-Pro-Asn-Ala-Pro-Tyr-Leu (SEQ ID NO: 1), wherein optionally 1 to 3 amino acids are deleted, substituted and/or added, such that the peptide has a cytotoxic T cell-inducing ability. The excipient is (a) an alpha hydroxyl acid selected from glycolic acid, lactic acid, malic acid, tartaric acid, citric acid and pharmacologically acceptable salts thereof, (b) a dicarboxylic acid selected from malonic acid, succinic acid, glutaric acid, maleic acid and pharmacologically acceptable salts thereof, and/or (c) methionine.